Brief: Creative Medical Technology Files Orphan Drug Designation Application With The U.S. FDA Using The Immcelz® Platform For The Treatment Of Brittle Type 1 Diabetes
23/03/2023 12:51
March 23 (Reuters) - Creative Medical Technology
Holdings Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY FILES ORPHAN DRUG DESIGNATION
APPLICATION WITH THE U.S. FDA USING THE IMMCELZ® PLATFORM FOR
THE TREATMENT OF BRITTLE TYPE 1 DIABETES
Source text for Eikon: ID:nPn15Zvgva
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM